Company news

AngioDynamics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes

September 18, 2024

AngioDynamics Announces CE Mark Approval in Europe for the Auryon System

September 2, 2024

AngioDynamics to Participate in Upcoming Investor Conferences

July 28, 2024

AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results

July 15, 2024

AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024

July 7, 2024

AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System

May 20, 2024

AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions

May 5, 2024

AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture

April 3, 2024

AngioDynamics Receives 510(k) Clearance for AlphaVac F18⁸⁵ System in Treatment of PE

April 3, 2024

AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.

March 31, 2024

AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024

March 18, 2024

AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference

March 5, 2024

AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million

February 14, 2024

AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease

January 22, 2024

AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance

January 4, 2024

AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024

December 6, 2023

AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism

December 6, 2023

AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance

October 3, 2023

AngioDynamics to Report Fiscal 2024 First Quarter Financial Results on October 4, 2023

September 11, 2023

AngioDynamics Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation

August 14, 2023

AngioDynamics Completes Enrollment for PRESERVE Clinical Study

August 2, 2023

AngioDynamics to Participate in a Fireside Chat at the Canaccord Genuity Growth Conference

July 30, 2023

AngioDynamics Announces Addition of Lorinda Burgess to Board of Directors

July 23, 2023

AngioDynamics Reports Fiscal Year 2023 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2024 Guidance

July 11, 2023

AngioDynamics to Report Fiscal 2023 Fourth Quarter and Full-Year Financial Results on July 12, 2023

June 19, 2023

AngioDynamics Announces Sale of Dialysis Product Portfolio and BioSentry Product to Merit Medical Systems for $100 Million

June 7, 2023

AngioDynamics to Present at the Needham Virtual Healthcare Conference

April 10, 2023

AngioDynamics Reports Fiscal 2023 Third Quarter Financial Results; Revises Guidance

March 29, 2023

AngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023

March 12, 2023

AngioDynamics to Participate in Three Investor Conferences in March

February 27, 2023

AngioDynamics Reports Fiscal 2023 Second Quarter Financial Results; Reaffirms Guidance

January 4, 2023

AngioDynamics to Report Fiscal 2023 Second Quarter Financial Results on January 5, 2023

December 14, 2022

AngioDynamics to Present at the Piper Sandler Healthcare Conference

November 16, 2022

AngioDynamics Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F18⁸⁵ PE System in Treatment of Pulmonary Embolism

October 30, 2022

AngioDynamics Reports Fiscal 2023 First Quarter Financial Results; Reaffirms Guidance

October 5, 2022

AngioDynamics to Report Fiscal 2023 First Quarter Financial Results on October 6, 2022

September 7, 2022

AngioDynamics to Present at the Canaccord Genuity Growth Conference

August 2, 2022

AngioDynamics Reports Fiscal Year 2022 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2023 Guidance

July 11, 2022

AngioDynamics to Report Fiscal 2022 Fourth Quarter and Full-Year Financial Results on July 12, 2022

June 14, 2022

AngioDynamics to Present at the UBS Global Healthcare Conference

May 15, 2022

AngioDynamics to Present at the BofA Securities Healthcare Conference

May 2, 2022

AngioDynamics Reports Fiscal 2022 Third Quarter Financial Results; Reaffirms Fiscal Year 2022 Guidance

April 6, 2022

AngioDynamics to Report Fiscal 2022 Third Quarter Financial Results on April 7, 2022

March 13, 2022

AngioDynamics to Present at Three Investor Conferences in March

March 7, 2022

PAVmed Appoints Shaun O’Neil as Chief Operating Officer

February 23, 2022

AngioDynamics to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

February 7, 2022

AngioDynamics Reports Fiscal 2022 Second Quarter Financial Results; Reaffirms Revenue Guidance; Revises Gross Margin and Adjusted EPS Guidance

January 5, 2022

AngioDynamics to Present at the Needham Virtual Growth Conference

January 2, 2022

AngioDynamics to Report Fiscal 2022 Second Quarter Financial Results on January 6, 2022

December 14, 2021

AngioDynamics Reports Fiscal 2022 First Quarter Financial Results; Updates Guidance

September 29, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 90 decks. Every deck is listed under its year.